Table 2

Comparison of the proportion of positive cases in each group

Pathological featuresIBM+RVPAMIBM+RV vs PAMIBM - RVPM&DMIBM - RV vs PM&DMIBM+RV vs IBM - RV
n (%)n (%)SensitivitySpecificityn (%)n (%)SensitivitySpecificityp value
Number of cases15 (100)7 (100)9 (100)11 (100)
Aggregated proteins, n (%)
 p6215 (100)6 (86)1.000.144 (44)3 (27)*0.440.730.003†
 TDP-4313 (87)5 (71)0.870.291 (11)2 (18)*0.110.820.001†
 Ubiquitin11 (73)4 (57)0.730.430 (0)3 (27)*0.000.730.001†
 Myotilin10 (67)5 (71)0.670.290 (0)9 (82)0.000.180.002†
 Congophilic deposits13 (87)7 (100)0.870.001 (11)0 (0)0.111.000.001†
COX−/SDH+ fibres‡, n (%)
 Any12 (86)2 (29)0.860.719 (100)3 (27)1.000.730.50
Inflammatory features, n (%)
 MHC class I upregulation15 (100)3 (43)1.000.579 (100)11 (100)1.000.001.00
 Strong MHC class I upregulation14 (93)0 (0)0.931.007 (78)10 (91)0.780.090.53
 Partial invasion10 (67)0 (0)0.671.003 (33)2 (18)0.330.820.21
 Endomysial CD3 T-cell score >113 (87)0 (0)0.871.004 (44)7 (64)0.440.360.06
 Endomysial CD4 T-cell score >112 (80)0 (0)0.801.002 (22)5 (45)0.220.540.01†
 Endomysial CD8 T-cell score >014 (93)0 (0)0.931.007 (78)9 (82)0.780.180.53
 Endomysial CD68 macrophage score >112 (80)0 (0)0.801.004 (44)8 (73)0.440.270.10
  • *Pathological features present in DM, but not PM cases.

  • †Statistically significant results.

  • ‡In IBM with rimmed vacuoles n=14.

  • COX, cytochrome oxidase; IBM, inclusion body myositis; MHC, major histocompatibility complex; PAM, protein accumulation myopathies with rimmed vacuoles; PM&DM, steroid-responsive inflammatory myopathies; RV, rimmed vacuoles; SDH, succinate dehydrogenase; TDP-43, transactivation response DNA binding protein-43.